Medical Uses
Rozebalamin (mecobalamin, also known as methylcobalamin) was approved in Japan on 24 September 2024 for slowing the progression of functional impairment in amyotrophic lateral sclerosis (ALS). It is an intramuscular injection: the approved adult dose is 50 mg twice a week. The Japanese label asks doctors to choose patients with the trial population in mind, which was people with early ALS (within one year of onset) who could still breathe well (%FVC above 60%).
Its exact mechanism in ALS is not known; mecobalamin, an active form of vitamin B12, acts as a coenzyme of methionine synthase and is thought to protect nerves from damage linked to homocysteine. Rozebalamin gives it at a far higher dose than ordinary vitamin B12 products. In the Japanese JETALS trial (130 patients, 16 weeks), the ALS functional rating score (ALSFRS-R) fell by 2.7 points with Rozebalamin compared with 4.6 points with placebo.
